Prevalence and Outcomes of Sepsis in Patients With Colon Carcinoma: Organism-Specific Analysis

结肠癌患者脓毒症的患病率和预后:病原体特异性分析

阅读:1

Abstract

Background Sepsis is a challenging condition, especially in patients with malignancy, that is associated with worse mortality and increased complications. This study aimed to analyze the prevalence of sepsis, its complications, healthcare outcomes, and associated organism-specific mortality in patients with colorectal carcinoma using the National Inpatient Sample database. Methodology We included patients aged >18 years with a primary diagnosis of colon cancer. The patients were divided into two groups, those with sepsis and those without sepsis. Confounders were adjusted using multivariate regression analysis. We examined outcomes including mortality, hospital charges, length of stay, and other associated complications. Results Out of 876,769 patients diagnosed with colon cancer, 2,579 (0.2%) had methicillin-resistant Staphylococcus aureus (MRSA) sepsis, 1,004 (0.1%) had Staphylococcus aureus sepsis, and 6,439 (0.7%) had Escherichia coli sepsis. Patients with sepsis exhibited significantly longer hospital stays, the highest with Staphylococcus aureus and Enterococcus, as well as increased healthcare costs compared to those without sepsis. The highest mortality rates were associated with Staphylococcus aureus (n = 169/1,004, 17%), followed by Pseudomonas (n = 150/940, 16%) and MRSA (n = 374/2,579, 14%). Sepsis also led to higher rates of complications, including acute kidney injury and septic shock. Conclusions Through this study, we aim to highlight the need for early diagnosis and targeted management of colon cancer patients who develop sepsis during their hospital course. Future research should focus on the underlying pathophysiology and effective interventions to improve outcomes for patients with colorectal carcinoma and sepsis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。